Skip to main content

MK-6482-012 An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-

NCT04736706

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Associated Conditions

Kidney Cancer

Principal Investigator

Sponsor

Merck

This trial is testing 3 combination therapies in people with a specific type of kidney cancer called advanced clear cell renal cell carcinoma (ccRCC). These 3 therapies are: (1) HIF triplet: pembrolizumab plus MK-6482 (belzutifan) and lenvatinib); (2) CTLA4 triplet: MK-1308A (pembrolizumab with MK-1308) plus lenvantinib; and (3) Doublet: Pembrolizumab plus lenvatinib. This trial is being done to: (a) Test the safety of the HIF and CTLA4 triplets compared to the doublet; (b) See how well the HIF and CTLA4 triplets work compared to the doublet; (c) See if participants who get the HIF and CTLA4 triplets live longer than those who get the doublet; and (d) See if participants who get the HIF and CTLA4 triplets have a better quality of life than those who get the doublet.

This study is currently enrolling.